MedTrace Logo

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

NCT00079924 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2007-05-25

No results posted yet for this study

Summary

Effects of Teriparatide in Postmenopausal Women Previously Treated with Alendronate or Raloxifene.

Conditions

  • Postmenopausal Osteoporosis

Interventions

DRUG

teriparatide

DRUG

aldrenodate

DRUG

raloxifene

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00079924 on ClinicalTrials.gov